The Pharmaceutical Market: Lithuania
THE PHARMACEUTICAL
MARKET OF LITHUANIA- REVIEW
We continue to hold our subdued outlook for
the Lithuanian pharmaceuticals market during the next few years, on
account of the changing economic and demographic situation. We expect
limited low single digit growth in 2012 , with the market expected to
increase by a local currency margin of 2.5% year-on-year (y-o-y) to
reach LTL1.6 8 bn (US$6 18 mn) in 2012 at consumer prices. However,
in US dollar terms, the market \' s value will shrink by 6.3%, in
dicating the challenges facing companies operating in the market .
Headline Expenditure Projections
- Pharmaceuticals: LTL1.64bn (US$659mn) in 2011 to LTL1.68bn (US$618mn) in 2012; +2.5% in local currency terms and -6.3% in US dollar terms. Forecastslightly upfrom Q4 12on account of new macroeconomic data.
- Healthcare: LTL6.99bn (US$2.81bn) in 2011 to LTL7.29bn (US$2.68bn) in 2012; +4.3% in local currency terms and -4.7% in US dollar terms. Forecast slightly up from Q4 12 on account of new macroeconomic data.
- Medical devices: LTL679mn (US$273mn) in 2011 to LTL749mn (US$276mn) in 2012; +10.3% in local currency terms and +0.8% in US dollar terms. Forecastslightly upfrom Q4 12on account of new macroeconomic data.
To
Browse a Full Report with TOC @
http://www.researchmoz.us/the-pharmaceutical-market-lithuania-report.html
Risk/Reward
Rating
In
our Q1 13 Pharmaceuticals Risk/Reward Rating (RRR) matrix, Lithuania
is 15th, out of the 20 markets surveyed in Emerging Europe, below its
Baltic peers. Although Lithuania boasts a largely risk-free operating
environment, its muted rewards prospects will continue to impact its
standing in the regional matrix. Globally, Lithuania ranks 60th out
of 95 markets surveyed.
Competitive
Landscape
The
competitive landscape section provides comparative company analyses
and rankings by US$ sales and % share of total sales - for the total
pharmaceutical sector, as well as the OTC, generics, and distribution
sub-sectors.
Table
of Contents
Executive
Summary7
SWOT
Analysis9
Lithuania
Pharmaceuticals And Healthcare Industry SWOT9
Lithuania
Political SWOT10
Lithuania
Economic SWOT10
Lithuania
Business Environment SWOT11
Pharmaceuticals
Risk/Reward Ratings12
Table:
Central And Eastern Europe Pharmaceuticals Risk/Reward Ratings,
Q21312
Rewards13
Risks13
Lithuania
- Market Summary15
Regulatory
Regime17
Regional
Harmonisation18
Pharmaceutical
Advertising19
Intellectual
Property Developments20
Pricing
Regime21
Pricing
Developments22
For More Information Kindly Contact:
ResearchMoz
Mr.
Nachiket Ghumare,
Tel:
866-997-4948
(Us-Canada
Toll Free)
Tel:
+1-518-621-2074
Website:
http://www.researchmoz.us
Comments
Post a Comment